Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending February 1, 2019. The report serves as a notification to the market regarding the Company's total voting rights and capital structure in conformity with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share capital and voting rights data.
- Issued Share Capital (as of Jan 31, 2019): 5,379,528,456 Ordinary Shares of 25 pence each.
- Treasury Shares: 414,605,950 Ordinary Shares.
- Total Voting Rights: 4,964,922,506.
Material Changes
The filing text does not provide a clear value or description of material changes versus the prior comparable period. It presents a static snapshot of share capital as of January 31, 2019.
Guidance, Outlook, and Risks
The filing text does not provide clear values or commentary regarding guidance, outlook, risks, contingencies, or unusual items. The document is a regulatory notification intended to assist shareholders in calculating notification thresholds under FCA rules.
Investor Verification Checklist
- Verify the total number of voting rights (4,964,922,506) against the latest FCA disclosure records.
- Confirm the number of shares held in Treasury (414,605,950) to ensure accurate denominator calculations for ownership thresholds.
- Review the Company's Form 20-F for comprehensive financial performance data, as this Form 6-K contains no financial results.